Drug Trial Radar · NCT06890884
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
594
Planned (sponsor's estimate)
Start
Apr 11, 2025
Primary completion
Dec 13, 2027
Study completion Dec 16, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.
Conditions
- Lymphoma, Large B-Cell, Diffuse
Interventions
Zilovertamab vedotinBiological
IV infusion
RituximabBiological
IV infusion
CyclophosphamideDrug
IV infusion
DoxorubicinDrug
IV infusion
Rituximab BiosimilarBiological
IV infusion
PrednisoneDrug
Oral administration or IV infusion
PrednisoloneDrug
Oral administration or IV infusion
Polatuzumab vedotinBiological
IV infusion
Rescue MedicationDrug
Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medication is Granulocyte Colony-Stimulating Factor (G-CSF).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response Rate (CRR) at End of Treatment (EOT) per Lugano Response CriteriaTime frame: Up to approximately 31 months
Locations
148 sites in 9 countries. Site status is shown where the registry gives one.
Infirmary Cancer Care ( Site 0157)
Mobile, Alabama · Recruiting
Ironwood Cancer & Research Centers ( Site 0204)
Chandler, Arizona · Recruiting
Palo Verde Cancer Specialists ( Site 0105)
Glendale, Arizona · Recruiting
City of Hope - Phoenix ( Site 0202)
Goodyear, Arizona · Recruiting
Genesis Cancer and Blood Institute ( Site 0193)
Hot Springs, Arkansas · Recruiting
Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135)
Burbank, California · Recruiting
City of Hope Comprehensive Cancer Center ( Site 0191)
Duarte, California · Recruiting
Moores Cancer Center ( Site 0187)
La Jolla, California · Recruiting
Bass Medical Group ( Site 0123)
Walnut Creek, California · Recruiting
Rocky Mountain Cancer Centers (RMCC) ( Site 8001)
Aurora, Colorado · Recruiting
Colorado West Healthcare System-Grand Valley Oncology ( Site 0165)
Grand Junction, Colorado · Recruiting
Medical Oncology Hematology Consultants (MOHC) ( Site 8007)
Newark, Delaware · Recruiting
Georgetown University Medical Center ( Site 0117)
Washington D.C., District of Columbia · Recruiting
Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130)
Boca Raton, Florida · Recruiting
Baptist MD Anderson Cancer Center ( Site 0176)
Jacksonville, Florida · Recruiting
Mount Sinai Braman Comprehensive Cancer Center ( Site 0140)
Miami Beach, Florida · Recruiting
Mid Florida Hematology and Oncology Center ( Site 0152)
Orange City, Florida · Recruiting
Beacon Cancer Care ( Site 0142)
Post Falls, Idaho · Recruiting
University of Chicago Medical Center ( Site 0126)
Chicago, Illinois · Recruiting
Illinois Cancer Care ( Site 7005)
Peoria, Illinois · Recruiting
University of Iowa-Holden Comprehensive Cancer Center ( Site 0139)
Iowa City, Iowa · Recruiting
Mission Blood & Cancer Care ( Site 0114)
Waukee, Iowa · Recruiting
Saint Elizabeth Medical Center Edgewood ( Site 0141)
Edgewood, Kentucky · Recruiting
Baptist Health Hardin ( Site 0154)
Elizabethtown, Kentucky · Recruiting
Baptist Health Lexington ( Site 0127)
Lexington, Kentucky · Recruiting
Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0185)
Louisville, Kentucky · Recruiting
Our Lady of the Lake Physician Group-Medical Oncology ( Site 0180)
Baton Rouge, Louisiana · Recruiting
Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0209)
Monroe, Louisiana · Recruiting
Ochsner Clinic Foundation ( Site 0189)
New Orleans, Louisiana · Recruiting
Louisiana State University Health Sciences Shreveport ( Site 0195)
Shreveport, Louisiana · Recruiting
Beth Israel Deaconess Medical Center ( Site 0161)
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute ( Site 0111)
Boston, Massachusetts · Recruiting
Minnesota Oncology Hematology (MNO) ( Site 8004)
Burnsville, Minnesota · Active not recruiting
Bozeman Health Deaconess Hospital ( Site 0183)
Bozeman, Montana · Recruiting
NHO Revive Research Institute, LLC ( Site 0121)
Lincoln, Nebraska · Recruiting
University Of Nebraska Medical Center ( Site 0110)
Omaha, Nebraska · Recruiting
Atlantic Health Morristown Medical Center ( Site 0163)
Morristown, New Jersey · Recruiting
Valley Health Systems - Ridgewood Campus ( Site 0125)
Paramus, New Jersey · Recruiting
Erie County Medical Center ( Site 0175)
Buffalo, New York · Completed
Roswell Park Cancer Institute ( Site 0192)
Buffalo, New York · Recruiting
Showing 40 of 148 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.